FDA opi­oid ad­comm chair blasts agency for 'will­ful blind­ness that bor­ders on the crim­i­nal'

In scathing re­marks di­rect­ed at the FDA’s han­dling of opi­oid ap­provals, the head of the agency’s ad­vi­so­ry pan­el has lam­bast­ed its “cozy, cozy re­la­tion­ships” with the phar­ma­ceu­ti­cal in­dus­try and called for a halt in con­sid­er­ing any new opi­oids for ap­proval.

Rae­ford Brown, chair of the FDA’s anes­thet­ic and anal­gesic drug prod­ucts ad­vi­so­ry com­mit­tee, did not pull any punch­es in his in­ter­view with the Guardian:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.